John E. Levine

19.6k total citations · 3 hit papers
201 papers, 9.5k citations indexed

About

John E. Levine is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, John E. Levine has authored 201 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Hematology, 47 papers in Oncology and 47 papers in Immunology. Recurrent topics in John E. Levine's work include Hematopoietic Stem Cell Transplantation (129 papers), Acute Myeloid Leukemia Research (45 papers) and Acute Lymphoblastic Leukemia research (34 papers). John E. Levine is often cited by papers focused on Hematopoietic Stem Cell Transplantation (129 papers), Acute Myeloid Leukemia Research (45 papers) and Acute Lymphoblastic Leukemia research (34 papers). John E. Levine collaborates with scholars based in United States, Germany and Canada. John E. Levine's co-authors include James L.M. Ferrara, Pavan Reddy, Ernst Holler, Thomas Braun, Sung Won Choi, Sophie Paczesny, Gregory A. Yanik, Andrew C. Harris, Carrie L. Kitko and Vincent T. Ho and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

John E. Levine

190 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Graft-versus-host disease

2009 1.8k citations James L.M. Ferrara, John E. Levine et al. profile →
Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease

2014 367 citations Ernst Holler, Karin Schmid‐Zalaudek et al. Biology of Blood and Marrow Transplantation profile →
EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

2018 266 citations James L.M. Ferrara, Daniel Wolff et al. Bone Marrow Transplantation profile →

Peers

Countries citing papers authored by John E. Levine

Since Specialization

Citations

This map shows the geographic impact of John E. Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Levine more than expected).

Fields of papers citing papers by John E. Levine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Levine. The network helps show where John E. Levine may publish in the future.

Co-authorship network of co-authors of John E. Levine

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Levine. A scholar is included among the top collaborators of John E. Levine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Levine. John E. Levine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation 2025 ·Blood Advances ·Bhavna Bhasin, Tao Wang, John E. Levine, Shalini Shenoy, Miguel‐Angel Perales, Asad Bashey, Hershel Raff, Wael Saber	0
2	Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn’s disease 2025 ·Gut ·(unknown), (unknown), Xiaoli Wang, (unknown), (unknown), Aaron Etra, Jean‐Frédéric Colombel, Christoph Schaniel, (unknown), John E. Levine, James L.M. Ferrara, Ling-Shiang Chuang, (unknown), (unknown), Bridget K. Marcellino, Ronald Hoffman, Judy H. Cho, Louis Cohen	1
3	Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study 2024 ·Transplant Infectious Disease ·Samantha E. Jacobs, Uroosa Ibrahim, (unknown), (unknown), (unknown), Usha Govindarajulu, Melissa Gitman, John E. Levine, Meenakshi Rana, Alla Keyzner	2
4	Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee 2024 ·Transplantation and Cellular Therapy ·Zainab Shahid, Aaron Etra, John E. Levine, Marcie Riches, Aliyah Baluch, Joshua A. Hill, Ryo Nakamura, Amir A. Toor, Celalettin Üstün, Jo‐Anne H. Young, Miguel‐Angel Perales, David J. Epstein, Hemant S. Murthy	3
5	Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell Transplantation (HCT) 2024 ·Transplantation and Cellular Therapy ·Santosh Putta, Bradford A. Young, Polly Pine, (unknown), Vian Amber, Wael Saber, John E. Levine, Stephan A. Grupp	0
6	Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects 2023 ·Science Translational Medicine ·(unknown), (unknown), Alberto Utrero‐Rico, Tatiana Goncharov, Joshua D. Webster, Ernst Holler, George Morales, Sergio Dellepiane, John E. Levine, Michael E. Rothenberg, Domagoj Vucic, James L.M. Ferrara	8
7	Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation 2023 ·Pediatric Blood & Cancer ·Carrie L. Kitko, Catherine M. Bollard, Mitchell S. Cairo, Joseph H. Chewning, Terry J. Fry, Michael A. Pulsipher, Shalini Shenoy, Donna A. Wall, John E. Levine	1
8	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience 2022 ·Bone Marrow Transplantation ·Jeffrey R. Andolina, Yi‐Cheng Wang, Lingyun Ji, David R. Freyer, John E. Levine, Michael A. Pulsipher, Alan S. Gamis, Richard Aplenc, Michael Roth, Lauren Harrison, Mitchell S. Cairo	6
9	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study 2021 ·Journal of Clinical Oncology ·Ran Reshef, Wael Saber, Javier Bolaños‐Meade, George Chen, Yi‐Bin Chen, Vincent T. Ho, Doris M. Ponce, Ryotaro Nakamura, Michael J. Martens, John A. Hansen, John E. Levine	15
10	A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd 2017 ·Blood ·Christoph Groth, (unknown), Manita Bremmers, Frank Preijers, Harry Dolstra, Tiago R. Matos, Christian Reicherts, (unknown), (unknown), John E. Levine, James L.M. Ferrara, Nicole M. A. Blijlevens, Matthias Stelljes, Walter J. F. M. van der Velden	1
11	CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity 2017 ·Blood ·Andrew M. Stein, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Bruce L. Levine, Carl H. June, (unknown), Sweta Shah, Mimi Leung, (unknown), (unknown), Rakesh Awasthi, Karen Thudium Mueller, Patricia A. Wood, Shannon L. Maude	3
12	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis 2016 ·Blood ·Shannon L. Maude, Michael A. Pulsipher, Michael W. Boyer, Stephan A. Grupp, Stella M. Davies, Christine L. Phillips, Michael R. Verneris, Keith J. August, Krysta Schlis, Timothy A. Driscoll, Rajen Mody, Christian M. Capitini, Carl H. June, Bruce L. Levine, Patricia A. Wood, Lan Yi, John E. Levine	59
13	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality 2015 ·Biology of Blood and Marrow Transplantation ·Margaret L. MacMillan, Marie Robin, Andrew C. Harris, Todd E. DeFor, Paul J. Martin, Amin Alousi, Vincent T. Ho, Javier Bolaños‐Meade, James L.M. Ferrara, Richard J. Jones, Mukta Arora, Bruce R. Blazar, Shernan G. Holtan, David A. Jacobsohn, Marcelo C. Pasquini, Gèrard Socié, Joseph H. Antin, John E. Levine, Daniel J. Weisdorf	161
14	Metagenomic analysis of the stool microbiome in patients receiving allogeneic SCT: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal GvHD 2014 ·University of Regensburg Publication Server (University of Regensburg) ·Ernst Holler, (unknown), Karin Schmid‐Zalaudek, Christian Hundsrucker, Josef Koestler, Katrin Peter, Wentao Zhu, Daniela Sporrer, Thomas Hehlgans, Marina Kreutz, Barbara Holler, Daniel Wolff, Matthias Edinger, Reinhard Andreesen, John E. Levine, James L.M. Ferrara, André Gessner, Rainer Spang, Peter J. Oefner	4
15	Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease breakdown → 2014 ·Biology of Blood and Marrow Transplantation ·Ernst Holler, (unknown), Karin Schmid‐Zalaudek, Christian Hundsrucker, Josef Koestler, Katrin Peter, Wentao Zhu, Daniela Sporrer, Thomas Hehlgans, Marina Kreutz, Barbara Holler, Daniel Wolff, Matthias Edinger, Reinhard Andreesen, John E. Levine, James L.M. Ferrara, André Gessner, Rainer Spang, Peter J. Oefner	367
16	Improved accuracy of acute graft-versus-host disease staging among multiple centers 2014 ·Best Practice & Research Clinical Haematology ·John E. Levine, William J. Hogan, Andrew C. Harris, Mark R. Litzow, Yvonne A. Efebera, Steven M. Devine, Ran Reshef, James L.M. Ferrara	15
17	Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study 2012 ·Blood ·John E. Levine, Brent R. Logan, Juan Wu, Amin M. Alousi, Javier Bolaños‐Meade, James L.M. Ferrara, Vincent T. Ho, Daniel J. Weisdorf, Sophie Paczesny	133
18	Treatment versus Transplant for Challenging Hematologic Disorders 2009 ·Biology of Blood and Marrow Transplantation ·Charles J. Parker, Robert A. Brodsky, John E. Levine	3
19	A biomarker panel for acute graft-versus-host disease 2008 ·Blood ·Sophie Paczesny, Oleg I. Krijanovski, Thomas Braun, Sung Won Choi, Shawn G. Clouthier, Rork Kuick, David E. Misek, Kenneth R. Cooke, Carrie L. Kitko, Angela C. Weyand, (unknown), Dawn Jones, Joel Whitfield, Pavan Reddy, John E. Levine, Samir Hanash, James L.M. Ferrara	290
20	Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Brian M. Alexander, Daniel S. Wechsler, Thomas Braun, John E. Levine, Joseph M. Herman, Gregory A. Yanik, Raymond J. Hutchinson, Lori J. Pierce	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact